Savara (SVRA) Stock
Savara (SVRA) closed at $4.64 on Nov 13, 2026; its Tenet Score is 32 of 100 against 409 Healthcare peers.
39 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Previous close
- $4.64
- Nov 13, 2026
- Market cap
- $1.0B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 4.03 – 7.00
- low → high
- Tenet Score
- 32/100
- Weak · 409 Healthcare peers
Industry: Drugs · see every company filed here →
Savara Inc scores 32/100. Weak. Strongest on financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 32 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.
Tenet Score · vs sector
n=409Factor grades
Growth omitted — no data yet.
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ~ Drawdown Context
- ~ Reversal Evidence
- ✕ Not-a-Value-Trap Gate
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 13, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Vor Biopharma IncVOR | 49 | $1.2B |
| GH Research PLCGHRS | 59 | $1.2B |
| Harrow IncHROW | 41 | $1.1B |
| Jade Biosciences IncJBIO | 63 | $1.1B |
| Faeth Therapeutics Inc.FTH | 43 | $1.0B |
| Verastem IncVSTM | 18 | $1.0B |
| Corvus Pharmaceuticals IncCRVS | 53 | $897.5M |
| MeiraGTx Holdings plcMGTX | 63 | $897.2M |
| 4D Molecular Therapeutics IncFDMT | 53 | $885.3M |
| Pharming Group N.V.PHAR | 41 | $884.1M |
Common questions
What sector and industry is Savara in?
Savara is in the Healthcare sector and the Drugs industry.
What is Savara's Tenet Score?
Savara's Tenet Score is 32 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.




